|
| | HR0011 | | LRB101 04755 ALS 49764 r |
|
|
| 1 | | HOUSE RESOLUTION
|
| 2 | | WHEREAS, The term Dystonia encompasses a broad group of |
| 3 | | debilitating, incurable neurological conditions in which |
| 4 | | scientists have not yet discovered a certain cause, making this |
| 5 | | illness extremely difficult to diagnose; and
|
| 6 | | WHEREAS, Nearly 250,000 Americans are living with |
| 7 | | dystonia, making it the third most common movement disorder, |
| 8 | | following essential tremor and Parkinson's disease; and
|
| 9 | | WHEREAS, The onset of dystonia is typically seen in early |
| 10 | | childhood, but it can also begin later in life during |
| 11 | | adolescence and adulthood; it has a lifelong span; and
|
| 12 | | WHEREAS, Currently, there is no cure for dystonia, only |
| 13 | | treatments to help ease symptoms, such as Botulinum toxin |
| 14 | | injections, deep brain stimulation, or other surgeries; and
|
| 15 | | WHEREAS, Recently, the Dystonia Coalition, a clinical |
| 16 | | research network for dystonia, has been established with |
| 17 | | support from the National Institute of Neurological Disorders |
| 18 | | and Stroke (NINDS) and the National Institutes of Health (NIH) |
| 19 | | Office of Rare Disease Research as part of the Rare Disease |
| 20 | | Clinical Research Network; and
|